Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates | MicrobiomeTrials← Back to trialsNCT07703514
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-10-09Est. Completion: 2027-04-12
Enrollment target: 60 participants Locations- University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States
Other microbiome trials you might be interested in
B-NHLB-Non Hodgkin LymphomaAcute Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaB-precursor ALLB-AllLymphoma, Non-HodgkinLeukemia, Lymphocytic, B CellB-Cell LymphomaB-Cell LeukemiaAcute Lymphoid Leukemia
Background:
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young a…
Bethesda, United StatesEst. completion Jul 1, 2027
Recruiting
Bronchitis, AcuteCommunity-acquired PneumoniaRespiratory Tract Infections
Children with lower respiratory tract infection (LRTI) are still often prescribed antibiotics in ways that depart from n…
Helsinki, FinlandEst. completion Dec 2029
Influenza, Human
The goal of this Phase II/III study is to investigate the safty and efficacy of 102D-6 in adolescents and adults with in…
Beijing, ChinaEst. completion Mar 30, 2027